期刊文献+

小牛脾提取物联合DP方案治疗卵巢癌的疗效观察 被引量:1

下载PDF
导出
摘要 目的:观察小牛脾提取物联合DP方案治疗卵巢癌的疗效。方法:选择2008年1月~2010年12月本院住院的晚期卵巢癌患者42例,根据用药方案的不同分为观察组和对照组各21例,观察组应用小牛脾提取物联合DP方案治疗,治疗组仅应用DP方案治疗,观察两组患者的疗效。结果:观察组有效率为33.33%;发生白细胞减少15例,血小板减少4例,脱发10例,满意率为80.95%。对照组有效率为23.81%;发生白细胞减少17例,血小板减少7例,脱发13例;满意率为52.38%。两组比较,差异有统计学意义。结论:应用小牛脾提取物联合DP方案治疗晚期宫颈癌,有效提高了患者的抵抗力及化疗过程中对身体的损伤,临床效果及不良反应的发生均优于单独使用DP方案化疗组,值得临床推广应用。
作者 赖寒
出处 《中国当代医药》 2011年第17期76-76,共1页 China Modern Medicine
  • 相关文献

参考文献5

  • 1Dowdy SC,Mullany SA,Brandt KR,et al.The utility of comput-ed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma[J].Cancer,2004,101(2):346-352.
  • 2Rinaldi M,Crino L,Scagliotti GV,et al.A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levelsa phase Ⅱ randomized trial[J].Ann-Oncol,2000,11 (10):1295-300.
  • 3赵晓东,张毅,张巧.高CA125的Ⅲ期卵巢上皮癌新辅助化疗的探讨[J].中国肿瘤临床,2005,32(5):264-268. 被引量:6
  • 4Eltabbakh GH,Mount SL,Beatty B,et al.Factors associated with cytoreducibility among women with ovarian carcinoma[J].Gynecol Oncol,2004,95(2):377-383.
  • 5黄守松,陈丽贤,傅文红,杜佩妍.晚期卵巢癌治疗方法对预后的影响[J].中国医药导报,2007,4(01Z):32-33. 被引量:5

二级参考文献19

  • 1温宏武,孙伟杰,郭燕燕,刘书文.晚期卵巢上皮性癌的预后变化及影响因素分析[J].中华妇产科杂志,1997,32(3):159-162. 被引量:15
  • 2Balat O. Paclitaxel/carboplatin versus cyclophosphamide/carboplatin in peritoneal carcinomatosis of the ovary[J]. Eur J Gynaecol Oncol, 2004, 25 (2): 195~196
  • 3Shibata K, Kikkawa F, Suzuki Y, et al. Neoadjuvant chemotherapy for FIGO stage Ⅲ or Ⅳ ovarian cancer: survival benefit and prognostic factors[J]. Int J Gynecol Cancer, 2003, 13(3):587~592
  • 4Chi DS, Liao JB, Leon LF, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma [J]. Gynecol Oncol,2001, 82(2): 532~537
  • 5Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery foradvanced ovarian carcinoma during the platinum era: a meta-analysis [J]. J Clin Oncol, 2002,20(5): 1248~1259
  • 6Kuhn W, Rutke S, Spathe K, et al. Neoadjvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in Intenational Federation of Gynecology and Obstetrics stage Ⅲ c ovarian carcinoma [J]. Cancer, 2001, 92 (10):2585 ~2591
  • 7Jacob JH, Gershenson DM, Morris M, et al. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer[J]. Gynecol Oncol, 1991, 42(2): 146~150
  • 8Vergote I, De Wever I, Tjalma W, et al. Neoadjvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma:a retrospective analysis of 285 patients [J]. Gynecol Oncol, 1998,71(3): 431~436
  • 9Ansquer Y, Leblanc E, Clough K, et al. Neoadjvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study [J]. Cancer, 2001, 91(12): 2329~2334
  • 10Schwartz PE, Rutherford TJ, Chambers JT, et al. Neoadjvant chemotherapy for advanced ovarian cancer: long-term survival[J].Gynecol Oncol, 1999, 729(1): 93~99

共引文献9

同被引文献13

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部